TC Biopharm () Statistics
Share Statistics
TC Biopharm () has 494.51K shares outstanding. The number of shares has increased by -51.14% in one year.
| Shares Outstanding | 494.51K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -89.65% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 296.56K |
| Failed to Deliver (FTD) Shares | 101.35K |
| FTD / Avg. Volume | 8.68% |
Short Selling Information
The latest short interest is 64.93K, so 20.32% of the outstanding shares have been sold short.
| Short Interest | 64.93K |
| Short % of Shares Out | 20.32% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 0.05 |
Valuation Ratios
The PE ratio is -0.13 and the forward PE ratio is -0.23.
| PE Ratio | -0.13 |
| Forward PE | -0.23 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.29 |
| P/FCF Ratio | -0.07 |
| PEG Ratio | n/a |
Enterprise Valuation
TC Biopharm () has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.2, with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.2 |
| Quick Ratio | 1.2 |
| Debt / Equity | 0.56 |
| Total Debt / Capitalization | 35.78 |
| Cash Flow / Debt | -7.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.2% and return on capital (ROIC) is -267.99%.
| Return on Equity (ROE) | -2.2% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | -267.99% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -144.07K |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.09M |
| Effective Tax Rate | 0.16 |
Stock Price Statistics
The stock price has increased by -97.98% in the last 52 weeks. The beta is 0.25, so TC Biopharm ()'s price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -97.98% |
| 50-Day Moving Average | 2.11 |
| 200-Day Moving Average | 8.08 |
| Relative Strength Index (RSI) | 25.98 |
| Average Volume (20 Days) | 1.17M |
Income Statement
In the last 12 months, TC Biopharm () had revenue of $0 and earned -$5.91M in profits. Earnings per share was $-191.21.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -14.24M |
| Net Income | -5.91M |
| EBITDA | -13.61M |
| EBIT | - |
| Earnings Per Share (EPS) | -191.21 |
Balance Sheet
The company has $2.46M in cash and $1.80M in debt, giving a net cash position of $661.45K.
| Cash & Cash Equivalents | 2.46M |
| Total Debt | 1.80M |
| Net Cash | 661.45K |
| Retained Earnings | -38.84M |
| Total Assets | 6.87M |
| Working Capital | 423.86K |
Cash Flow
In the last 12 months, operating cash flow was -$10.54M and capital expenditures -$110.35K, giving a free cash flow of -$10.66M.
| Operating Cash Flow | -10.54M |
| Capital Expenditures | -110.35K |
| Free Cash Flow | -10.66M |
| FCF Per Share | -344.92 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TCBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -36771.15% |
| FCF Yield | -83583.49% |
Analyst Forecast
The average price target for TCBP is $3, which is 476.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 476.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 5, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Aug 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -14.71 |
| Piotroski F-Score | 3 |